Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tom J Parry

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
European Journal of Pharmacology|December 21, 2016
Effects of neuregulin GGF2 (cimaglermin alfa) dose and treatment frequency on left ventricular function in rats following myocardial infarctionTom J Parry, Anindita Ganguly, Erika L Troy, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|October 4, 2024
Improvement in edema and cognitive recovery after moderate traumatic brain injury with the neurosteroid prodrug NTS-104Alyssa F Balleste, Jacqueline C Alvarez, Fabiola Placeres-Uray, et al.
Journal of Medicinal Chemistry|September 8, 2009
Nonpeptide urotensin-II receptor antagonists: a new ligand class based on piperazino-phthalimide and piperazino-isoindolinone subunitsEdward C Lawson, Diane K Luci, Shyamali Ghosh, et al.
Stroke|September 28, 2022
Pharmacological Characterization of a Novel Neuroactive Steroid Prodrug, NTS-104, and Its Neuroprotective Activity in Experimental Stroke ModelsLi Zhang, Robin Schwartz-Byrne, Steven Gertz, et al.
Bioorganic & Medicinal Chemistry Letters|October 16, 2007
Phenylpiperidine-benzoxazinones as urotensin-II receptor antagonists: synthesis, SAR, and in vivo assessmentDiane K Luci, Shyamali Ghosh, Charles E Smith, et al.
Journal of Cardiovascular Pharmacology|January 7, 2010
Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibitionMargery A Connelly, Tom J Parry, Edward C Giardino, et al.
Journal of the American Heart Association|October 25, 2014
Anti-remodeling and anti-fibrotic effects of the neuregulin-1β glial growth factor 2 in a large animal model of heart failureCristi L Galindo, Ehab Kasasbeh, Abigail Murphy, et al.
Plos One|February 26, 2013
Intravenous glial growth factor 2 (GGF2) isoform of neuregulin-1β improves left ventricular function, gene and protein expression in rats after myocardial infarctionMichael F Hill, Amish V Patel, Abigail Murphy, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
European Journal of Pharmacology|December 21, 2016
Effects of neuregulin GGF2 (cimaglermin alfa) dose and treatment frequency on left ventricular function in rats following myocardial infarctionTom J Parry, Anindita Ganguly, Erika L Troy, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|October 4, 2024
Improvement in edema and cognitive recovery after moderate traumatic brain injury with the neurosteroid prodrug NTS-104Alyssa F Balleste, Jacqueline C Alvarez, Fabiola Placeres-Uray, et al.
Journal of Medicinal Chemistry|September 8, 2009
Nonpeptide urotensin-II receptor antagonists: a new ligand class based on piperazino-phthalimide and piperazino-isoindolinone subunitsEdward C Lawson, Diane K Luci, Shyamali Ghosh, et al.
Stroke|September 28, 2022
Pharmacological Characterization of a Novel Neuroactive Steroid Prodrug, NTS-104, and Its Neuroprotective Activity in Experimental Stroke ModelsLi Zhang, Robin Schwartz-Byrne, Steven Gertz, et al.
Bioorganic & Medicinal Chemistry Letters|October 16, 2007
Phenylpiperidine-benzoxazinones as urotensin-II receptor antagonists: synthesis, SAR, and in vivo assessmentDiane K Luci, Shyamali Ghosh, Charles E Smith, et al.
Journal of Cardiovascular Pharmacology|January 7, 2010
Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibitionMargery A Connelly, Tom J Parry, Edward C Giardino, et al.
Journal of the American Heart Association|October 25, 2014
Anti-remodeling and anti-fibrotic effects of the neuregulin-1β glial growth factor 2 in a large animal model of heart failureCristi L Galindo, Ehab Kasasbeh, Abigail Murphy, et al.
Plos One|February 26, 2013
Intravenous glial growth factor 2 (GGF2) isoform of neuregulin-1β improves left ventricular function, gene and protein expression in rats after myocardial infarctionMichael F Hill, Amish V Patel, Abigail Murphy, et al.
Pageof 3